

Organon & Co. (OGN)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001821825

Organon & Co.

OGN; healthcare

Grade

E

A B C D E

▼

weakest fifth of 371 graded peers
percentile 85.4; sampling error 2.5 points; lower is stronger

Rank

317 of 371

Profitability

C/D

■

percentile 60.0

Solvency

D

■

percentile 74.5

Growth and financing

C

■

percentile 54.2

Reliability

0.94 AUC

filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025

Peer failure rate

0.52% a year

Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

over \$2.67B assets

total assets \$12.9B

Standard universe

inside

revenue above \$1M and assets above \$10M

Warnings

none active

not computable: distress

Inputs computable

8 of 14

Graded from

filings received through Feb 24, 2026

227 days before the rescans; latest periodic filing 10-Q received Jul 31, 2026

Last close

\$13.76

2026-10-08; market equity \$3.6B

Price used in grade

None



E, the bear

weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Nov Jan Mar May Jul Sep

Rescans on file: E from Mar 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

Organon & Co. ("Organon," the "Company," "we," "our," or "us") is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women's health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 60.0						
Gross profitability		25.7%	32.2%	55.8	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(4.0%)	(6.6%)	66.4	811	2025-12-31
Gross margin stability, five years		3.4 pts	2.8 pts	57.9	243	2025-12-31
Solvency, sleeve percentile 74.5						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		1.82x	2.96x	74.5	839	2025-12-31
Growth and financing, sleeve percentile 54.2						
Revenue growth, three-year compound		0.2%	10.0%	70.5	415	2025-12-31
Free cash flow growth, three-year compound		(6.7%)	10.9%	82.1	96	2025-12-31
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		5.5%	2.1%	39.5	704	2025-12-31
Net share issuance, one year		0.9%	2.5%	24.6	634	2026-02-17

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
312	Opko Health, Inc. (OPK)	84.1	E	fortress
				balance sheet
313	Amarin Corp. Plc\Uk (AMRN)	84.3	E	fortress
				balance sheet
314	Kalaris Therapeutics, Inc. (KLRS)	84.6	E	dilution
315	Journey Medical Corp. (DERM)	84.9	E	
316	Amgen Inc. (AMGN)	85.1	E	
317	Organon & Co. (OGN) <	85.4	E	
318	Sonoma Pharmaceuticals, Inc. (SNOA)	85.7	E	dilution,
				fortress
				balance sheet
319	Outset Medical, Inc. (OM)	85.9	E	dilution
320	National Vision Holdings, Inc. (EYE)	86.2	E	
321	Natural Alternatives International Inc. (NAII)	86.5	E	dilution, late
				filer, fortress
				balance sheet
322	DarioHealth Corp. (DRIO)	86.8	E	dilution, short
				runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	29.9%	8.0%	65
Distance from 52-week high	(0.3%)	(31.4%)	97
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	14.9%	(1.0%)	95
Book value to price	0.28	0.28	50
Sales to price	1.72	0.31	88
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.05	(0.14)	65

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$1.1B
Operating cash flow, four quarters	\$737.0M
Months of runway	not finite
Days since last periodic filing	70 (10-Q received Jul 31, 2026)
Median daily dollar volume, 63 sessions	\$30.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$3.3B	2025-12-31	2026-02-24	10-K	0001628280-26-011125

2	assets	us-gaap:Assets	\$12.9B	2025-12-31	2026-02-24	10-K	0001628280-26-011125
3	net income	us-gaap:NetIncomeLoss	\$187.0M	2025-12-31	2026-02-24	10-K	0001628280-26-011125
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$700.0M	2025-12-31	2026-02-24	10-K	0001628280-26-011125
5	assets	us-gaap:Assets	\$13.1B	2024-12-31	2026-02-24	10-K	0001628280-26-011125
6	revenue	us-gaap:Revenues	\$6.2B	2025-12-31	2026-02-24	10-K	0001628280-26-011125
7	gross profit	us-gaap:GrossProfit	\$3.7B	2024-12-31	2026-02-24	10-K	0001628280-26-011125
8	revenue	us-gaap:Revenues	\$6.4B	2024-12-31	2026-02-24	10-K	0001628280-26-011125
9	revenue	us-gaap:Revenues	\$6.3B	2023-12-31	2026-02-24	10-K	0001628280-26-011125
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.5B	2023-12-31	2026-02-24	10-K	0001628280-26-011125
11	revenue	us-gaap:Revenues	\$6.2B	2022-12-31	2025-11-10	10-K/A	0001104659-25-108693
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.3B	2022-12-31	2025-11-10	10-K/A	0001104659-25-108693
13	revenue	us-gaap:Revenues	\$6.3B	2021-12-31	2024-02-26	10-K	0001628280-24-006733
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.4B	2021-12-31	2024-02-26	10-K	0001628280-24-006733
15	current assets	us-gaap:AssetsCurrent	\$4.4B	2025-12-31	2026-02-24	10-K	0001628280-26-011125
16	current liabilities	us-gaap:LiabilitiesCurrent	\$2.4B	2025-12-31	2026-02-24	10-K	0001628280-26-011125
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$162.0M	2025-12-31	2026-02-24	10-K	0001628280-26-011125
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$939.0M	2024-12-31	2026-02-24	10-K	0001628280-26-011125
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$175.0M	2024-12-31	2026-02-24	10-K	0001628280-26-011125
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	\$799.0M	2023-12-31	2024-02-26	10-K	0001628280-24-006733
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$251.0M	2023-12-31	2026-02-24	10-K	0001628280-26-011125
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	\$858.0M	2022-12-31	2024-02-26	10-K	0001628280-24-006733
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$196.0M	2022-12-31	2025-11-10	10-K/A	0001104659-25-108693
24	assets	us-gaap:Assets	\$12.1B	2023-12-31	2025-11-10	10-K/A	0001104659-25-108693
25	assets	us-gaap:Assets	\$11.0B	2022-12-31	2024-02-26	10-K	0001628280-24-006733
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	260,315,650	2026-02-17	2026-02-24	10-K	0001628280-26-011125
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	257,950,149	2025-02-25	2025-11-10	10-K/A	0001104659-25-108693